{"nctId":"NCT03349333","briefTitle":"A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL","startDateStruct":{"date":"2015-09-10","type":"ACTUAL"},"conditions":["Refractory Peripheral T-Cell Lymphoma","Relapsed T-Cell Lymphoma"],"count":85,"armGroups":[{"label":"pralatrexate","type":"EXPERIMENTAL","interventionNames":["Drug: pralatrexate","Dietary Supplement: Vitamin B12 and folic acid"]}],"interventions":[{"name":"pralatrexate","otherNames":[]},{"name":"Vitamin B12 and folic acid","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject has histologically/cytologically confirmed PTCL, using the World Health Organization (WHO) disease classification:\n\n   1. PTCL not otherwise specified (NOS)\n   2. Angioimmunoblastic T-cell lymphoma\n   3. Anaplastic large cell lymphoma, ALK+\n   4. Anaplastic large cell lymphoma, ALK-\n   5. Extranodal NK/T-cell lymphoma - nasal type\n   6. Enteropathy-associated T cell lymphoma\n   7. Hepatosplenic T-cell lymphoma\n   8. Subcutaneous panniculitis-like T-cell lymphoma\n   9. Adult T-cell lymphoma/leukemia (human T-cell leukemia virus \\[HTLV\\] 1+)\n   10. Aggressive NK-cell leukemia\n   11. Transformed mycosis fungoides\n2. Subject has to have documented progressive disease (PD) after at least 1 prior systemic treatment.\n3. Subject may not have received an experimental drug or biologic as their only prior therapy. Subject must have clear PD after the last treatment received. Subject should have at least 1 biopsy from initial diagnosis or in the relapsed setting to confirm the diagnosis of PTCL. Subject must have recovered from the toxic effects of prior therapy.\n4. Subjects with an enlarged lymph node or extranodal mass lesion clearly measurable in two perpendicular directions and greater than 1.5 cm maximum diameter on computed tomography performed within 14 days prior to study enrollment.\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.\n6. At least 18 years of age.\n7. Expected life expectancy ≥ 3 months.\n8. Adequate hematological, hepatic, and renal function as defined by:\n\n   * Absolute neutrophil count (ANC) ≥ 1000/uL (or 1\\*109/L), platelet count ≥ 100,000/uL (or 100\\*109/L) (at both screening and within 3 days prior to dosing on cycle 1, day 1)\n   * Total bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 X upper limit of normal (ULN) (AST/ALT \\< 5 X ULN if documented hepatic involvement with lymphoma)\n   * Creatinine ≤ 1.5 mg/dL (or 132.6 µmol/L) or a calculated creatinine clearance ≥ 50 mL/min\n9. Women of childbearing potential must have agreed to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate and must have a negative serum pregnancy test within 14 days prior to the first day of study treatment. Subjects who are postmenopausal for at least 1 year (\\> 12 months since last menses) or are surgically sterilized did not require this test.\n10. Men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 90 days after the last administration of pralatrexate.\n11. Subject gives written informed consent (IC).\n\nExclusion Criteria:\n\n1. Subject has:\n\n   1. Precursor T-cell lymphoma or leukemia\n   2. T-cell prolymphocytic leukemia (T-PLL)\n   3. T-cell large granular lymphocytic leukemia\n   4. Mycosis fungoides, other than transformed mycosis fungoides\n   5. Sézary syndrome\n   6. Primary cutaneous CD30+ T-cell disorders: Lymphoid papulosis and primary cutaneous anaplastic large cell lymphoma\n2. Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 5 years.\n3. Congestive heart failure Class III/IV according to the New York Heart Association's Heart Failure guidelines.\n4. Human immunodeficiency virus (HIV)-positive diagnosis.\n5. Has, or history of, brain metastases or central nervous system (CNS) disease.\n6. Active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the subject to receive protocol treatment.\n7. Has major surgery within 2 weeks of study entry.\n8. Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study.\n9. Receipt of corticosteroids within 7 days of study treatment, unless subject has been taking a continuous systemic dose of no more than 10 mg/day or equivalent dose of prednisone, or a local or inhaled or intranasal administration at fixed doses for at least 1 month prior to study treatment and tumor shrinkage was not observed.\n10. Use of any investigational drugs, biologics, or devices within 4 weeks prior to study treatment or planned use during the course of the study.\n11. Receipt of anti-tumor antibody therapy within 100 days prior to study treatment.\n12. History of allogeneic hematopoietic stem cell transplantation. Or subjects with a history of autologous hematopoietic stem cell transplantation within 100 days prior to study treatment.\n13. Previous exposure to pralatrexate.\n14. Subject is pregnant or breast-feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate(ORR) by International Working Group Criteria","description":"ORR defined as the percentage of subjects with CR, CRu or PR as Best Overall Response.Evaluation of response must be performed within 7 days prior to the projected first dose of cycle 2-4 and then within 7 days prior to the projected first dose of every even-numbered subsequent cycle (i.e. prior to cycles 6, 8, etc). Unscheduled radiological response assessments will be performed earlier if clinical progression is suspected.The primary analysis will be conducted once all subjects have completed cycle 5 treatment or discontinued before. Study treatment may continue per investigator judgment for a maximum of 24 months.\n\nResponse will be assessed on the basis of clinical, radiological, and pathological criteria. Response will be assessed by independent central review and by the treating investigator. Central review assessors will be blinded to the response assessments by the treating investigator. The primary analysis will be based on response assessed by central review.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Response (TTR)","description":"Time to response was measured from first day of treatment to the first date of documented response.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0947","spread":"1.6590"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"PFS was measured from treatment day 1 until event or censoring. An event was defined as the earliest of the following: death from any cause or disease progression. Subjects undergoing transplant or any other subsequent therapy prior to documentation of PD was censored at that time. Progression of disease deems as 1. 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders, 2.Appearance of any new lesion during or at the end of therapy as per IWC criteria.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.76","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was measured from treatment day 1 until death or censoring.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Responses","description":"Duration of response was measured from first day of documented response to disease progression or death, whatever comes first.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.67","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Treatment Emergent Adverse Events","description":"treatment emergent AE was scheduled to be collected during all subject visits, the data evaluated as clinical significant will be summarized and presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve [AUC] for R-pralatrexate","description":"The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2350.7402","spread":"28.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3979.1069","spread":"152.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3586.2925","spread":"43.70"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve [AUC] for S-pralatrexate","description":"The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1364.7686","spread":"22.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2182.5078","spread":"264.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1674.8773","spread":"38.32"}]}]}]},{"type":"SECONDARY","title":"Steady State Volume of Distribution [Vdss] for R-pralatrexate","description":"The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"194.1589","spread":"87.4028"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344.2511","spread":"109.8671"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"329.1892","spread":"251.4938"}]}]}]},{"type":"SECONDARY","title":"Steady State Volume of Distribution [Vdss] for S-pralatrexate","description":"The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"517.1628","spread":"292.2888"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1110.6541","spread":"548.2687"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1680.6116","spread":"2292.0216"}]}]}]},{"type":"SECONDARY","title":"Steady State Clearance [CLss] for R-pralatrexate","description":"The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1914","spread":"6.7903"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3789","spread":"5.3859"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8406","spread":"8.9265"}]}]}]},{"type":"SECONDARY","title":"Steady State Clearance [CLss] for S-pralatrexate","description":"The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.6341","spread":"17.9816"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.9794","spread":"8.4317"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.2022","spread":"22.4576"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Plasma Concentration [Cmax] for R-pralatrexate","description":"The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4649.6811","spread":"83.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2488.1502","spread":"17.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5064.6667","spread":"421.48"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Plasma Concentration [Cmax] for S-pralatrexate","description":"The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3727.8582","spread":"118.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2325.5105","spread":"24.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3439.9695","spread":"697.55"}]}]}]},{"type":"SECONDARY","title":"Time of Cmax Observation [Tmax] for R-pralatrexate","description":"The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1000","spread":null}]}]}]},{"type":"SECONDARY","title":"Time of Cmax Observation [Tmax] for S-pralatrexate","description":"The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1000","spread":null}]}]}]},{"type":"SECONDARY","title":"Terminal Phase Half-life [t1/2Z] for R-pralatrexate","description":"The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5040","spread":"3.4927"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6089","spread":"0.1970"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8249","spread":"4.3282"}]}]}]},{"type":"SECONDARY","title":"Terminal Phase Half-life [t1/2Z] for S-pralatrexate","description":"The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8634","spread":"5.6517"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2505","spread":"7.7381"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8987","spread":"23.2607"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":71},"commonTop":["Stomatitis","Neutropenia"]}}}